Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

Abstract

Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.

Crick authors

Crick First author
Crick Corresponding author